{ "version": "2.2", "instance": { "acst-20230930.htm": { "nsprefix": "acst", "nsuri": "http://www.acastipharma.com/20230930", "dts": { "inline": { "local": [ "acst-20230930.htm" ] }, "schema": { "local": [ "acst-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "acst-20230930_cal.xml" ] }, "definitionLink": { "local": [ "acst-20230930_def.xml" ] }, "labelLink": { "local": [ "acst-20230930_lab.xml" ] }, "presentationLink": { "local": [ "acst-20230930_pre.xml" ] } }, "keyStandard": 194, "keyCustom": 34, "axisStandard": 14, "axisCustom": 0, "memberStandard": 22, "memberCustom": 21, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 2 }, "contextCount": 137, "entityCount": 1, "segmentCount": 45, "elementCount": 455, "unitCount": 6, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 30, "http://fasb.org/us-gaap/2023": 438 }, "report": { "R1": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "longName": "100010 - Statement - Condensed Consolidated Interim Balance Sheet (Unaudited)", "shortName": "Condensed Consolidated Interim Balance Sheet (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical", "longName": "100020 - Statement - Condensed Consolidated Interim Balance Sheet (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Interim Balance Sheet (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_5aa4eb3f-7476-4fef-9a4b-b903d1a85ea4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5aa4eb3f-7476-4fef-9a4b-b903d1a85ea4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited", "longName": "100030 - Statement - Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_6b8a110f-b531-4a67-9d42-1a4ff54e0cb0", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6b8a110f-b531-4a67-9d42-1a4ff54e0cb0", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "unique": true } }, "R5": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited", "longName": "100040 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholder's Equity (Unaudited)", "shortName": "Condensed Consolidated Interim Statements of Changes in Shareholder's Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_1c315306-5b7f-497c-a3f8-032df1fe3e40", "name": "us-gaap:SharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6b27dc2e-8c4b-4d01-8c8e-ff72a1fcb545", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "unique": true } }, "R6": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "longName": "100050 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Interim Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_6b8a110f-b531-4a67-9d42-1a4ff54e0cb0", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "unique": true } }, "R7": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation", "longName": "100060 - Disclosure - Note 1 - Nature of Operation", "shortName": "Note 1 - Nature of Operation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "100070 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-3-recent-accounting-pronouncements", "longName": "100080 - Disclosure - Note 3 - Recent Accounting Pronouncements", "shortName": "Note 3 - Recent Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4Receivables", "longName": "100090 - Disclosure - Note 4 - Receivables", "shortName": "Note 4 - Receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_86ba51ae-a982-4af3-87f4-258c848fddd3", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_86ba51ae-a982-4af3-87f4-258c848fddd3", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-", "longName": "100110 - Disclosure - Note 5 - Short-term Investments", "shortName": "Note 5 - Short-term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6TradeAndOtherPayables", "longName": "100130 - Disclosure - Note 6 - Trade and other payables", "shortName": "Note 6 - Trade and other payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7Leases", "longName": "100140 - Disclosure - Note 7 - Leases", "shortName": "Note 7 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquity1", "longName": "100160 - Disclosure - Note 9 - Capital and Other Components of Equity", "shortName": "Note 9 - Capital and Other Components of Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensation", "longName": "100170 - Disclosure - Note 10 - Stock Based Compensation", "shortName": "Note 10 - Stock Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShare", "longName": "100180 - Disclosure - Note 11 - Loss per share", "shortName": "Note 11 - Loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosure1", "longName": "100190 - Disclosure - Note 11 - Supplemental Cash Flow Disclosure", "shortName": "Note 11 - Supplemental Cash Flow Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote12FinancialInstruments", "longName": "100200 - Disclosure - Note 12- Financial instruments", "shortName": "Note 12- Financial instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingencies", "longName": "100210 - Disclosure - Note 14 - Commitments and Contingencies", "shortName": "Note 14 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14Restructuring", "longName": "100220 - Disclosure - Note 14 - Restructuring", "shortName": "Note 14 - Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-significant-accounting-policies-policies", "longName": "100240 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsTables", "longName": "100250 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4ReceivablesTables", "longName": "100260 - Disclosure - Note 4 - Receivables (Tables)", "shortName": "Note 4 - Receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-tables", "longName": "100270 - Disclosure - Note 5 - Short-term Investments (Tables)", "shortName": "Note 5 - Short-term Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6TradeAndOtherPayablesTables", "longName": "100300 - Disclosure - Note 6 - Trade and other payables (Tables)", "shortName": "Note 6 - Trade and other payables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityTables", "longName": "100310 - Disclosure - Note 9 - Capital and Other Components of Equity (Tables)", "shortName": "Note 9 - Capital and Other Components of Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesTables", "longName": "100320 - Disclosure - Note 7 - Leases (Tables)", "shortName": "Note 7 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationTables", "longName": "100330 - Disclosure - Note 10 - Stock Based Compensation (Tables)", "shortName": "Note 10 - Stock Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareTables", "longName": "100340 - Disclosure - Note 11 - Loss per share (Tables)", "shortName": "Note 11 - Loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureTables", "longName": "100350 - Disclosure - Note 11 - Supplemental Cash Flow Disclosure (Tables)", "shortName": "Note 11 - Supplemental Cash Flow Disclosure (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:CashFlowOperatingCapitalTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:CashFlowOperatingCapitalTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual", "longName": "100370 - Disclosure - Note 1 - Nature of Operation (Details Textual)", "shortName": "Note 1 - Nature of Operation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_ebba4bb5-87dc-4ba1-b34a-9860c37af875", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ebba4bb5-87dc-4ba1-b34a-9860c37af875", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "100380 - Disclosure - Fair Value Measurements (Additional Information) (Details)", "shortName": "Fair Value Measurements (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "longName": "100390 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)", "shortName": "Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "acst:GuaranteedInvestmentCertificatesAndTermDeposits", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "acst:GuaranteedInvestmentCertificatesAndTermDeposits", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails", "longName": "100400 - Disclosure - Note 4 - Receivables - Receivables (Details)", "shortName": "Note 4 - Receivables - Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "acst:SalesTaxReceivablesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "acst:SalesTaxReceivablesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureReceivablesAdditionalInformationDetails", "longName": "100410 - Disclosure - Receivables (Additional Information) (Details)", "shortName": "Receivables (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_6b8a110f-b531-4a67-9d42-1a4ff54e0cb0", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_86ba51ae-a982-4af3-87f4-258c848fddd3", "name": "acst:ReductionOfResearchAndDevelopmentExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "unique": true } }, "R36": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details", "longName": "100420 - Disclosure - Note 5 - Short-term Investments - Marketable Securities (Details)", "shortName": "Note 5 - Short-term Investments - Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:MarketableSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:MarketableSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals", "longName": "100430 - Disclosure - Note 5 - Short-term Investments - Marketable Securities (Details) (Parentheticals)", "shortName": "Note 5 - Short-term Investments - Marketable Securities (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_9d86b3f1-5c64-49f2-b77f-90d112f3944a", "name": "us-gaap:InvestmentInterestRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9d86b3f1-5c64-49f2-b77f-90d112f3944a", "name": "us-gaap:InvestmentInterestRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6TradeAndOtherPayablesTradeAndOtherPayablesDetails", "longName": "100490 - Disclosure - Note 6 - Trade and other payables - Trade and other payables (Details)", "shortName": "Note 6 - Trade and other payables - Trade and other payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails", "longName": "100500 - Disclosure - Note 7 -Leases - Schedule of Lease Costs Recognized for Operating Leases (Details)", "shortName": "Note 7 -Leases - Schedule of Lease Costs Recognized for Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails", "longName": "100510 - Disclosure - Note 7 - Leases - Schedule of Future Minimum Lease Payments (Details)", "shortName": "Note 7 - Leases - Schedule of Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesAdditionalInformationDetails", "longName": "100520 - Disclosure - Note 7 - Leases (Additional Information) (Details)", "shortName": "Note 7 - Leases (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails", "longName": "100530 - Disclosure - Note 9 - Capital and Other Components of Equity - Schedule Of Derivative Liabilities At Fair Value (Details)", "shortName": "Note 9 - Capital and Other Components of Equity - Schedule Of Derivative Liabilities At Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_6453be70-f5cb-4ac5-b85a-8999317b9528", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6453be70-f5cb-4ac5-b85a-8999317b9528", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails", "longName": "100540 - Disclosure - Note 9 - Capital and Other Components of Equity - Fair Value Measurement Inputs and Valuation Techniques (Details)", "shortName": "Note 9 - Capital and Other Components of Equity - Fair Value Measurement Inputs and Valuation Techniques (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_37e67c39-3dc0-4117-989f-d83c5991dd41", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_37e67c39-3dc0-4117-989f-d83c5991dd41", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "longName": "100550 - Disclosure - Note 9 - Capital and Other Components of Equity (Details Textual)", "shortName": "Note 9 - Capital and Other Components of Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_29781d72-6d9d-42f4-8ee4-358d9a3d60f6", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_417da1b1-559f-4d6e-8e3a-9777de0c5203", "name": "acst:AtthemarketSalesAgreementCommonStockMaximumAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "unique": true } }, "R45": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual", "longName": "100560 - Disclosure - Note 10 - Stock Based Compensation (Details Textual)", "shortName": "Note 10 - Stock Based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "acst:UnrecognizedCompensationCostRelatedToNonVestedShareOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "acst:UnrecognizedCompensationCostRelatedToNonVestedShareOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails", "longName": "100570 - Disclosure - Note 10 - Stock Based Compensation - Activities Within the Stock Option Plan (Details)", "shortName": "Note 10 - Stock Based Compensation - Activities Within the Stock Option Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_37a28060-2c0a-46a8-b5cf-5129b46a93f7", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c55faf01-ec2b-49a1-a414-c8164206f3ab", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "unique": true } }, "R47": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails", "longName": "100580 - Disclosure - Note 10 - Stock-based Compensation - Schedule of weighted average grant date fair value of awards for options granted (Details)", "shortName": "Note 10 - Stock-based Compensation - Schedule of weighted average grant date fair value of awards for options granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "acst:SharesPrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "unique": true } }, "R48": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "longName": "100590 - Disclosure - Note 10 - Stock Based Compensation - Compensation Expense (Details)", "shortName": "Note 10 - Stock Based Compensation - Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_6b8a110f-b531-4a67-9d42-1a4ff54e0cb0", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ba5ee71e-e54b-45e5-b657-463c05405807", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "unique": true } }, "R49": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "longName": "100600 - Disclosure - Note 11 - Loss per share - Schedule of diluted net loss per share attributable to common shareholders (Details)", "shortName": "Note 11 - Loss per share - Schedule of diluted net loss per share attributable to common shareholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails", "longName": "100610 - Disclosure - Note 11 - Supplemental Cash Flow Disclosure - Changes in Working Capital Items (Details)", "shortName": "Note 11 - Supplemental Cash Flow Disclosure - Changes in Working Capital Items (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:IncreaseDecreaseInReceivables", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "us-gaap:IncreaseDecreaseInReceivables", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual", "longName": "100620 - Disclosure - Note 14 - Commitments and Contingencies (Details Textual)", "shortName": "Note 14 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_04531e25-7d7e-4978-bfac-608d55638d06", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14RestructuringAdditionalInformationDetails", "longName": "100630 - Disclosure - Note 14 - Restructuring (Additional Information) (Details)", "shortName": "Note 14 - Restructuring (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_bd591628-bf8d-4a22-8e90-d7d53f88c325", "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd591628-bf8d-4a22-8e90-d7d53f88c325", "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual", "longName": "100650 - Disclosure - Note 16 - Subsequent events (Details Textual)", "shortName": "Note 16 - Subsequent events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_587041cc-ec30-4637-b05c-316914be13cc", "name": "acst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "acst-20230930.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "acst_CommonClassDAndCommonClassEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CommonClassDAndCommonClassEMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Common Class D and Common Class E [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, B, or C, representing ownership interest in a corporation." } } }, "auth_ref": [] }, "us-gaap_CommonClassCMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassCMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Class C [Member]", "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11Revenues" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r140", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Measurement Input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": [ "r388" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r641" ] }, "acst_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "AtTheMarketOfferingMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "At-the-market Offering [Member]", "documentation": "Represents information regarding an at-the-market offering." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersOfFinancialAssetsAccountedForAsSaleValuationTechiques", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "changes in valuation techniques", "label": "Transfers of Financial Assets Accounted for as Sale, Valuation Techniques", "documentation": "Description of the valuation techniques or other methods used to estimate the fair value of assets obtained or liabilities incurred in transfers of financial assets accounted for as sales. If a valuation model is used, the description would be expected to include quantitative and qualitative information about the assumptions used in the valuation model (for example, but not limited to, discount rates, anticipated credit losses, and prepayment speeds)." } } }, "auth_ref": [ "r24" ] }, "acst_SalesTaxReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "SalesTaxReceivablesCurrent", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Sales tax receivables", "documentation": "Carrying amount as of the balance sheet date of sales taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "terseLabel": "Sales tax receivables" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupAbstract", "lang": { "en-us": { "role": { "label": "Asset, Held-for-Sale, Not Part of Disposal Group [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents are comprised of:", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "acst_TaxYear2039Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2039Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2039 [Member]", "documentation": "Identified as tax year 2039.", "terseLabel": "2039" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r48", "r49" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r643" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash from financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r168" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash Equivalents, at Carrying Value, Total", "periodEndLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r655", "r736" ] }, "acst_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "EquityIncentivePlanMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan [Member]", "documentation": "Represents the equity incentive plan." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r41", "r149", "r603" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r296", "r325", "r326", "r327", "r328", "r329", "r330", "r386", "r434", "r435", "r436", "r616", "r617", "r619", "r620", "r621" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash from investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r168" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: interest", "negatedLabel": "Less: interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r420" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r99", "r100", "r101" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r60" ] }, "acst_TaxYear2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2033Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2033 [Member]", "documentation": "Identified as tax year 2033.", "terseLabel": "2033" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows used in operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r31", "r172", "r252", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r366", "r367", "r368", "r393", "r527", "r607", "r640", "r685", "r727", "r728" ] }, "acst_ClassECommonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ClassECommonMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Class E Common [Member]", "documentation": "Class E Common" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r63" ] }, "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson": { "xbrltype": "percentItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person", "label": "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson", "documentation": "Maximum number of shares that may be issued to one person in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "totalLabel": "Purchase Obligation, Total", "terseLabel": "Purchase Obligation, Total", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r414" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax Credit Carryforward", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r61" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "totalLabel": "Goodwill, Total", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r150", "r267", "r466", "r611", "r628", "r681", "r682" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DepreciationExpenseOnReclassifiedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationExpenseOnReclassifiedAssets", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation Expense on Reclassified Assets", "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense)." } } }, "auth_ref": [ "r50", "r51" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss per share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r194", "r203", "r204", "r205" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r63" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "acst_TaxYear2041Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2041Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2041 [Member]", "documentation": "Information pertaining to 2041.", "terseLabel": "2041" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r141", "r152", "r153", "r154", "r172", "r197", "r198", "r200", "r202", "r208", "r209", "r252", "r287", "r289", "r290", "r291", "r294", "r295", "r299", "r300", "r302", "r305", "r312", "r393", "r492", "r493", "r494", "r495", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r511", "r529", "r554", "r572", "r594", "r595", "r596", "r597", "r598", "r647", "r663", "r668" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r414" ] }, "acst_WarrantsIssuedDecember272017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "WarrantsIssuedDecember272017Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Issued December 27, 2017 [Member]", "documentation": "Represents warrants issued December 27, 2017." } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "acst_DerivativeLiabilitiesChangeInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "DerivativeLiabilitiesChangeInFairValue", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value", "label": "Derivative Liabilities Change in fair value", "documentation": "Derivative Liabilities Change in fair value" } } }, "auth_ref": [] }, "us-gaap_ExchangeFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExchangeFees", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Fees related to share-for-share issuance for merger with Grace", "label": "Exchange Fees", "terseLabel": "Fees related to share-for-share issuance for merger with Grace", "documentation": "The amount of expense in the period for fees charged by securities exchanges for the privilege of trading securities listed on that exchange. Some fees vary with the related volume, while others are fixed." } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardLineItems", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Extension of lease term, description", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r415" ] }, "acst_StockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "StockOptionPlanMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Stock Option Plan [Member]", "documentation": "Represents the stock option plan." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r87", "r117", "r476", "r628", "r664", "r680", "r717" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r60" ] }, "acst_September2023UsPrivateOfferingPreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "September2023UsPrivateOfferingPreFundedWarrantMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "September 2023 US private offering pre-funded warrant Member", "documentation": "September 2023 US private offering pre-funded warrant Member" } } }, "auth_ref": [] }, "acst_TaxYear2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2034Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2034 [Member]", "documentation": "Identified as tax year 2034.", "terseLabel": "2034" } } }, "auth_ref": [] }, "acst_StockIssuedSharesWarrantsExercisableShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "StockIssuedSharesWarrantsExercisableShares", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Issued Warrents Exercisable", "label": "Stock Issued Shares Warrants Exercisable Shares", "documentation": "Stock issued shares warrants exercisable" } } }, "auth_ref": [] }, "acst_ProceedsFromNRCIRAP": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ProceedsFromNRCIRAP", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from NRC IRAP", "label": "acst_ProceedsFromNRCIRAP", "documentation": "The cash inflow from the National Research Council of Canada Industrial Research Assistance Program." } } }, "auth_ref": [] }, "acst_IncreaseDecreaseInNonCashWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "IncreaseDecreaseInNonCashWorkingCapital", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase decrease in non-cash working capital.", "label": "Increase Decrease in Non Cash Working Capital", "negatedTotalLabel": "Increase (Decrease) in Non-cash Working Capital", "totalLabel": "Total changes in operating assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardTable", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Table]", "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances." } } }, "auth_ref": [ "r60" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r414" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r385", "r386" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r13", "r23", "r26", "r70", "r71", "r72", "r73", "r74", "r75", "r77", "r78", "r79", "r108" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6TradeAndOtherPayablesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivables", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r155", "r538" ] }, "acst_AssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "AssetPurchaseAgreementMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Asset Purchase Agreement [Member]", "label": "Asset Purchase Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation of equipment", "totalLabel": "Depreciation, Total", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r52" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Selling and Marketing Expense, Total", "label": "Selling and Marketing Expense", "negatedLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r642" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote12FinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial instruments", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r91" ] }, "us-gaap_OtherSellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Other Selling, General and Administrative Expense", "documentation": "Amount of selling, general and administrative expense classified as other." } } }, "auth_ref": [ "r92" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r642" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative translation adjustment", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r6" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r37", "r38", "r88", "r156", "r474", "r487", "r490" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r642" ] }, "us-gaap_CashFlowOperatingCapitalTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowOperatingCapitalTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in working capital items", "label": "Cash Flow, Operating Capital [Table Text Block]", "documentation": "Tabular disclosure of the net increase (decrease) in operating capital in the operating section of the statement of cash flows, represents the entire footnote disclosure that provides details regarding the net change during the reporting period of all assets and liabilities used in operating activities." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r349" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r642" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Additional lease renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r722" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r418", "r627" ] }, "us-gaap_InvestmentCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCreditMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Investment Tax Credit Carryforward [Member]", "terseLabel": "Investment credit [Member]", "documentation": "Investment tax credit carryforwards arising from certain qualifying capital expenditures including, but not limited to, rehabilitation, energy, advanced coal project and gasification project." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r18", "r19" ] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details" ], "lang": { "en-us": { "role": { "totalLabel": "Marketable Securities, Total", "label": "Marketable Securities", "terseLabel": "Total short-term investments", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r68", "r656" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share, Diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r166", "r184", "r185", "r186", "r187", "r188", "r197", "r200", "r201", "r202", "r206", "r380", "r381", "r467", "r480", "r606" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "terseLabel": "Functional Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r397" ] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherRestructuringMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote15RestructuringCostScheduleOfRestructuringChargesAndPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Other Restructuring [Member]", "terseLabel": "Legal", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r612", "r613", "r614", "r615" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r83", "r628", "r739" ] }, "us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentEffectsOnEarningsPerShareLineItems", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "Impairment Effects on Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Remaining Minimum Amount Committed", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": [ "r80", "r116" ] }, "us-gaap_ImpairmentEffectsOnEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentEffectsOnEarningsPerShareTable", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "Impairment Effects on Earnings Per Share [Table]", "documentation": "Disclosure of information about the effects of asset impairment charge on per share or per unit basis." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Payment Arrangement, Option, Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r20", "r21", "r57" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Value", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r82", "r473", "r628" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r59" ] }, "us-gaap_SaleLeasebackTransactionNetBookValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleLeasebackTransactionNetBookValue", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "totalLabel": "Sale Leaseback Transaction, Net Book Value, Total", "label": "Sale Leaseback Transaction, Net Book Value", "terseLabel": "Net book value", "documentation": "The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller." } } }, "auth_ref": [ "r125", "r126", "r127", "r725" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r113" ] }, "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Financial Support to Nonconsolidated Legal Entity [Domain]", "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds." } } }, "auth_ref": [ "r0", "r497", "r498" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r106" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating cash flows for operating lease", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r416", "r627" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r297", "r310", "r376", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r479", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r676", "r677", "r678", "r679" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Lease term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r721" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of short-term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r97" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r99" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Translations effects on cash and cash equivalents related to reporting currency", "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r720" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from issuance under the at-the-market (ATM) program", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r8" ] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r41", "r99", "r169" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use asset and lease liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r417", "r627" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r356", "r357", "r470" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureReceivablesAdditionalInformationDetails", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses, net of government assistance", "totalLabel": "Research and Development Expense, Total", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r69", "r355", "r735" ] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-tables" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Equipment held-for-sale, impairment loss", "label": "Impairment of Long-Lived Assets to be Disposed of", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r11", "r104" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r34", "r67", "r471", "r528" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r625" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r413" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r84", "r111", "r475", "r486", "r490", "r496", "r530", "r628" ] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4Receivables" ], "lang": { "en-us": { "role": { "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "Receivables", "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": [ "r670" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r269", "r274", "r557" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r109", "r281", "r282", "r600", "r684" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r274", "r557" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4IntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r268" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Price", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r297", "r310", "r376", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r479", "r610", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r676", "r677", "r678", "r679" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss and total comprehensive loss for the period", "label": "Net Income (Loss)", "verboseLabel": "Net loss for the period", "totalLabel": "Net loss and total comprehensive loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r90", "r101", "r121", "r146", "r161", "r162", "r165", "r172", "r180", "r184", "r185", "r186", "r187", "r190", "r191", "r199", "r210", "r213", "r215", "r217", "r252", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r381", "r393", "r478", "r553", "r570", "r571", "r608", "r638", "r685" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r175", "r176", "r177", "r207", "r462", "r491", "r511", "r521", "r522", "r523", "r524", "r525", "r526", "r529", "r532", "r533", "r534", "r535", "r536", "r539", "r540", "r541", "r542", "r544", "r545", "r546", "r547", "r548", "r550", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r633" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r644" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables", "totalLabel": "Receivables, Net, Current, Total", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r628" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r716" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income and other expense", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r93", "r211" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r716" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r645" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operating activities", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r210", "r213", "r215", "r217", "r608" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r716" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r64" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common shares, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r82" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "totalLabel": "Disposal Group, Including Discontinued Operation, Assets, Current, Total", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r70", "r76", "r105", "r107", "r145", "r146" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r33", "r148", "r172", "r252", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r366", "r367", "r368", "r393", "r628", "r685", "r727", "r728" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsToCompleteContractsInProcess": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsToCompleteContractsInProcess", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "commitments", "label": "Commitments to Complete Contracts in Process", "documentation": "General description of commitments which may be required in performing under a construction-type contract which are outside the ordinary course of business at the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r716" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r646" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r630", "r631", "r632", "r634", "r635", "r636", "r637", "r665", "r666", "r715", "r737", "r742" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r141", "r152", "r153", "r154", "r172", "r197", "r198", "r200", "r202", "r208", "r209", "r252", "r287", "r289", "r290", "r291", "r294", "r295", "r299", "r300", "r302", "r305", "r312", "r393", "r492", "r493", "r494", "r495", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r511", "r529", "r554", "r572", "r594", "r595", "r596", "r597", "r598", "r647", "r663", "r668" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r742" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r716" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "terseLabel": "Issue and Sold Aggregate Common Shares", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r82" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r404", "r429" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r82", "r529", "r549", "r742", "r743" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "General and administrative expenses", "totalLabel": "General and Administrative Expense, Total", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r92", "r556" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r642" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r157", "r265", "r266", "r604" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r196", "r202" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageFairvalue": { "xbrltype": "percentItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageFairvalue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted weighted average fair value", "label": "Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Weighted Average FairValue", "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Weighted Average FairValue" } } }, "auth_ref": [] }, "acst_PurchaseOfCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "PurchaseOfCommonShares", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "label": "purchase of common shares", "documentation": "purchase of common shares" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails": { "parentTag": "acst_IncreaseDecreaseInNonCashWorkingCapital", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables", "negatedLabel": "Receivables", "totalLabel": "Increase (Decrease) in Receivables, Total", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "acst_ScheduleOfGovernmentAssistanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ScheduleOfGovernmentAssistanceTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Government Assistance [Table Text Block]", "documentation": "The tabular disclosure for government assistance.", "terseLabel": "Schedule of Government Assistance" } } }, "auth_ref": [] }, "acst_CommonStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CommonStockDividendRatePercentage", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Dividend Rate, Percentage", "label": "acst_CommonStockDividendRatePercentage", "documentation": "The percentage rate used to calculate dividend payments on common stock." } } }, "auth_ref": [] }, "acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales": { "xbrltype": "percentItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales", "label": "acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales", "documentation": "The percentage of each sale that is to be paid to the underwriter under the at-the-market sales agreement." } } }, "auth_ref": [] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "acst_BrokerWarrantsIssuedDecember2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "BrokerWarrantsIssuedDecember2017Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Broker Warrants Issued December 2017 [Member]", "documentation": "Represents broker warrants issued December 2017." } } }, "auth_ref": [] }, "acst_GovernmentAssistance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "GovernmentAssistance", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Government Assistance", "label": "acst_GovernmentAssistance", "documentation": "The amount of government assistance recorded in earnings." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "terseLabel": "Foreign exchange gain (loss)", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r551", "r638", "r718", "r719", "r740" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r195", "r202" ] }, "acst_WarrantsIssuedInMay2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "WarrantsIssuedInMay2018Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Warrants Issued in May 2018 [Member]", "documentation": "Represents warrants issued in May 2018." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering warrants", "verboseLabel": "Number outstanding (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r91" ] }, "acst_TaxYear2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2030Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2030 [Member]", "documentation": "Identified as tax year 2030.", "terseLabel": "2030" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "acst_InvestmentTaxCreditReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "InvestmentTaxCreditReceivables", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceGovernmentAssistanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Investment Tax Credit Receivables", "label": "Investment Tax Credit Receivables", "terseLabel": "Investment tax credit" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r642" ] }, "acst_GuaranteedInvestmentCertificatesAndTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "GuaranteedInvestmentCertificatesAndTermDeposits", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guaranteed investment certificates and term deposits classified as cash equivalents", "label": "Guaranteed investment certificates and term deposits", "documentation": "Guaranteed investment certificates and term deposits" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities", "terseLabel": "reserves or liabilities", "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from estimated policyholder reserves, which will be deductible from future taxable income when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the tax deduction to be taken." } } }, "auth_ref": [ "r62", "r714" ] }, "acst_CommissionCostsRelatedToShareSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CommissionCostsRelatedToShareSale", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Commission Costs Related to Share Sale", "label": "acst_CommissionCostsRelatedToShareSale", "documentation": "Represents the amount of commission costs recognized during the period related to share sale." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "acst_ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ProceedsFromIssuanceOfCommonSharesFromExerciseOfStockOptions", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common shares from exercise of stock options", "label": "Proceeds From Issuance Of Common Shares From Exercise Of Stock Options", "documentation": "Proceeds From Issuance Of Common Shares From Exercise Of Stock Options" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r332", "r333", "r347", "r348", "r350", "r623" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 }, "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of warrant liabilities", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Change in fair value of warrant liabilities", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r2", "r11" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "acst_TaxYear2038Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2038Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2038 [Member]", "documentation": "Identified as tax year 2038.", "terseLabel": "2038" } } }, "auth_ref": [] }, "acst_CommonWarrantsSharesParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CommonWarrantsSharesParValue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Common share par value", "label": "Common Warrants Shares par value", "documentation": "Common Warrants Shares par value" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "acst_ExpectedVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ExpectedVolatility", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Expected volatility", "documentation": "Expected volatility" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r175", "r176", "r177", "r207", "r462", "r491", "r511", "r521", "r522", "r523", "r524", "r525", "r526", "r529", "r532", "r533", "r534", "r535", "r536", "r539", "r540", "r541", "r542", "r544", "r545", "r546", "r547", "r548", "r550", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r633" ] }, "acst_FairValueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "FairValueMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value [Member]", "label": "Fair value [Member]", "documentation": "Fair value [Member]" } } }, "auth_ref": [] }, "acst_ExpectedWarrantLifeLiability": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ExpectedWarrantLifeLiability", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "label": "Expected warrant life liability", "documentation": "Expected warrant life liability" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquity1" ], "lang": { "en-us": { "role": { "terseLabel": "Capital and other components of equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r110", "r171", "r298", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r314", "r377", "r575", "r576", "r599" ] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14Restructuring" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r270", "r271", "r273", "r276", "r280" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amount", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "acst_WriteOffOfEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "WriteOffOfEquipment", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "documentation": "Write Off Of Equipment", "label": "Write Off Of Equipment", "terseLabel": "Write off of equipment" } } }, "auth_ref": [] }, "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price", "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumption Exercise Price.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumption Exercise Price", "verboseLabel": "Exercise price" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Machinery and Equipment, Gross", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ "r106" ] }, "acst_NetProceedsCommonSharesAmont": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "NetProceedsCommonSharesAmont", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Net Proceeds Common Shares Amont", "label": "Net Proceeds Common shares amont", "documentation": "Net Proceeds Common shares amont" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r112" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r642" ] }, "acst_StockOptionsExercisePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "StockOptionsExercisePrice", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Stock Options Exercise Price", "documentation": "Stock Options Exercise Price" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r173", "r174", "r424", "r425", "r426", "r427", "r522", "r523", "r524", "r525", "r526", "r548", "r550", "r577" ] }, "acst_FurnitureAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "FurnitureAndOfficeEquipmentMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Office Equipment [Member]", "documentation": "Represents information regarding furniture and office equipment." } } }, "auth_ref": [] }, "acst_EffectOfTranslationEffectOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "EffectOfTranslationEffectOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate fluctuations on cash and cash equivalents", "totalLabel": "Effect of exchange rate fluctuations on cash and cash equivalents, Total", "label": "Effect of exchange rate fluctuations on cash and cash equivalents", "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies." } } }, "auth_ref": [] }, "acst_DerivativeWarrantLiabilitiesOutstandings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "DerivativeWarrantLiabilitiesOutstandings", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Warrant Liabilities Fair Value", "label": "Derivative Warrant Liabilities Outstandings", "documentation": "Derivative Warrant Liabilities Outstandings" } } }, "auth_ref": [] }, "us-gaap_InvestmentInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentInterestRate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Investment Interest Rate", "documentation": "Rate of interest on investment." } } }, "auth_ref": [ "r578", "r579", "r580", "r581", "r582", "r583", "r592", "r593", "r632", "r672", "r674" ] }, "acst_UsDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "UsDepositsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details" ], "lang": { "en-us": { "role": { "label": "US Deposits [Member]", "documentation": "US Deposits [Member]" } } }, "auth_ref": [] }, "acst_WarrantIssuedDuringYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "WarrantIssuedDuringYear", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued during the year", "label": "Warrant Issued during year", "documentation": "Warrant Issued during year" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "acst_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded Warrants [Member]", "label": "Pre-funded Warrants [Member]", "documentation": "Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "acst_RKOSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "RKOSupplyAgreementMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "RKO Supply Agreement [Member]", "documentation": "Represents the RKO Supply Agreement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r15", "r111" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total shareholder\u2019s equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r82", "r85", "r86", "r103", "r531", "r549", "r573", "r574", "r628", "r640", "r664", "r680", "r717", "r742" ] }, "acst_ReductionOfResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ReductionOfResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction of research and development", "label": "Reduction Of Research And Development Expenses", "documentation": "Reduction Of Research And Development Expenses" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r671", "r726" ] }, "acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Award in Non-dilutive and Non-repayable Funding From NRC IRAP", "label": "acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP", "documentation": "The amount of award in non-dilutive and non-repayable funding from National Research Council of Canada Industrial Research Assistance Program." } } }, "auth_ref": [] }, "acst_DerivativeLiabilityWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "DerivativeLiabilityWarrantsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability Warrants [Member]", "documentation": "Represents derivative liability warrants." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCosts", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs", "documentation": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs" } } }, "auth_ref": [] }, "acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "negatedLabel": "Write-off of deferred financing fees related to at-the-market (ATM) program", "terseLabel": "Write Off of Deferred Financing Costs of At-the-Market Program", "label": "Write off of deferred financing costs of at-the-market (ATM) program", "documentation": "Represents the amount recognized during the period for the write off of deferred financing costs of at-the-market (ATM) program." } } }, "auth_ref": [] }, "acst_NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "NetProceedsFromIssuanceOfCommonSharesAndWarrantsFromPrivatePlacement", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of common shares and warrants from private placement", "label": "Net Proceeds From Issuance Of Common Shares And Warrants From Private Placement", "documentation": "Net Proceeds From Issuance Of Common Shares And Warrants From Private Placement" } } }, "auth_ref": [] }, "us-gaap_InvestmentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentMaturityDate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Investment Maturity Date", "documentation": "Maturity date of investment, in YYYY-MM-DD format." } } }, "auth_ref": [ "r578", "r579", "r580", "r581", "r582", "r583", "r592", "r593", "r632", "r673", "r675" ] }, "acst_ShareBasedCompensationArrangementByShareBasedValueOfAwardsForOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedValueOfAwardsForOptionsGranted", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "weighted average grant fair value of awards for options granted", "label": "Share Based Compensation Arrangement By Share Based value of Awards for Options Granted", "documentation": "Share Based Compensation Arrangement By Share Based value of Awards for Options Granted" } } }, "auth_ref": [] }, "acst_ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ResearchAndDevelopmentContractsAndContractResearchOrganizationsAgreementsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development contracts and contract research organizations agreements", "label": "Research and development contracts and contract research organizations agreements [Member]", "documentation": "Research and development contracts and contract research organizations agreements [Member]" } } }, "auth_ref": [] }, "acst_CanadianDepositsOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CanadianDepositsOneMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details" ], "lang": { "en-us": { "role": { "label": "Canadian Deposits One [Member]", "documentation": "Canadian Deposits One [Member]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Restructuring cost", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Restructuring cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r272", "r275", "r277", "r279" ] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r63", "r65", "r66" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, number of options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r337" ] }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "label": "Expired, weighted average fair value (in CAD per share)", "documentation": "The weighted average grant-date fair value of options expired during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [] }, "acst_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ReverseStockSplitMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "Related to reverse stock split." } } }, "auth_ref": [] }, "acst_TaxYear2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2031Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2031 [Member]", "documentation": "Identified as tax year 2031.", "terseLabel": "2031" } } }, "auth_ref": [] }, "acst_TaxYear2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2032Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2032 [Member]", "documentation": "Identified as tax year 2032.", "terseLabel": "2032" } } }, "auth_ref": [] }, "acst_CostRelatedToProspectusSupplementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CostRelatedToProspectusSupplementAmount", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Cost Related to Prospectus Supplement Amount", "label": "Cost Related to Prospectus Supplement Amount", "terseLabel": "Cost related to prospectus supplement amount" } } }, "auth_ref": [] }, "acst_CommonStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CommonStockRedemptionPricePerShare", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Redemption Price Per Share (in CAD per share)", "label": "acst_CommonStockRedemptionPricePerShare", "documentation": "Amount to be paid per share at which the common stock of an entity is redeemed or may be called at." } } }, "auth_ref": [] }, "acst_CommonWarrantsSharesParValueExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CommonWarrantsSharesParValueExercisePrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Common Warrants Shares Par Value Exercise Price", "label": "Common Warrants Shares Par Value Exercise Price", "documentation": "Common Warrants Shares Par Value Exercise Price" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Rent", "terseLabel": "Payments for rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails": { "parentTag": "acst_IncreaseDecreaseInNonCashWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "terseLabel": "Trade and other payables", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation", "totalLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r58", "r81", "r82", "r111" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r387" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r45", "r46", "r47", "r131", "r132", "r133", "r134" ] }, "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageFairvalue": { "xbrltype": "percentItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageFairvalue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised weighted average fair value", "label": "Share based Compensation Arrangement By Share based Payment Award Options Exercised In Period Weighted Average FairValue", "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Exercised In Period Weighted Average FairValue" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, Beginning Balance", "periodEndLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r129", "r472", "r510", "r537", "r628", "r640", "r655" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liabilities", "label": "Derivative Liability", "totalLabel": "Derivative Liability, Total", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r159", "r160", "r392", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r544", "r546", "r547", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r605", "r738" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from shares issued under the at-the-market (ATM) program", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r15", "r81", "r82", "r111", "r499", "r572", "r595", "r639" ] }, "acst_TaxYear2035Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2035Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2035 [Member]", "documentation": "Identified as tax year 2035.", "terseLabel": "2035" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated life (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r342" ] }, "acst_CommonWarrantAndPreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CommonWarrantAndPreFundedWarrantMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Common Warrant and Pre-Funded Warrant [Member]", "documentation": "Common Warrant and Pre-Funded Warrant [Member]" } } }, "auth_ref": [] }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, weighted average fair value", "documentation": "The weighted average fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Exercised, weighted average fair value (in CAD per share)" } } }, "auth_ref": [] }, "acst_PurchasePricePerCommonShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "PurchasePricePerCommonShare", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "label": "Purchase Price per common share", "documentation": "Purchase Price per common share" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Inventories, Total", "label": "Increase (Decrease) in Inventories", "terseLabel": "Inventory", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6TradeAndOtherPayablesTradeAndOtherPayablesDetails", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade and other payables", "totalLabel": "Accounts Payable and Accrued Liabilities, Current, Total", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Total trade and other payables", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r30" ] }, "acst_ConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ConsultantMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Consultant [Member]", "documentation": "Represents consultant." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r296", "r325", "r326", "r327", "r328", "r329", "r330", "r434", "r435", "r436", "r616", "r617", "r619", "r620", "r621" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Financial Liabilities Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Common shares issued in relation to merger with Grade via share-for-share", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r15", "r35", "r111" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Changes in operating assets and liabilities", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfLeaseCostsRecognizedForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r419", "r627" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon the exercise of stock options, Value", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r15", "r35", "r111" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets (a)", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r70", "r76", "r105", "r107" ] }, "acst_SaleOfStockAveragePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "SaleOfStockAveragePricePerShare", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock, Average Price Per Share (in dollars per share)", "label": "acst_SaleOfStockAveragePricePerShare", "documentation": "The average price per share received by entity for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Costs Recognized for Operating Leases", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r723" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote15RestructuringCostScheduleOfRestructuringChargesAndPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r272", "r273", "r277", "r278" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from shares issued under the at-the-market (ATM) program (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r15", "r81", "r82", "r111", "r492", "r572", "r595" ] }, "acst_GrantsAndInvestmentTaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "GrantsAndInvestmentTaxCreditReceivable", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total government assistance", "label": "Government assistance", "terseLabel": "Government assistance", "documentation": "GrantsAndInvestmentTaxCreditReceivable" } } }, "auth_ref": [] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote15RestructuringCostScheduleOfRestructuringChargesAndPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Employee severance", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Nature Of Operations", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r130", "r139" ] }, "acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "UnrecognizedCompensationCostRelatedToNonVestedShareOptions", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Unrecognized compensation cost related to non-vested share options", "label": "Unrecognized compensation cost related to non-vested share options" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockNameDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": [ "r42", "r43", "r44" ] }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, Weighted average grant date fair value beginning period", "periodEndLabel": "Outstanding, Weighted average grant date fair value period end", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue", "documentation": "The weighted average fair value of options outstanding during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r7", "r23", "r145" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "2025 and thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote15RestructuringTables" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Schedule of restructuring charges and payments", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r53", "r54", "r55" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Stock based compensation (in shares)", "totalLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r15", "r81", "r82", "r111" ] }, "acst_CommonStockValuePerCommonShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CommonStockValuePerCommonShare", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Per Common Share", "label": "Common Stock value Per Common Share", "documentation": "Common Stock value Per Common Share" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6TradeAndOtherPayablesTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade payables", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Derivative Liabilities At Fair Value", "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r115", "r151", "r172", "r210", "r214", "r216", "r252", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r365", "r367", "r393", "r469", "r543", "r628", "r640", "r685", "r686", "r727" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "acst_ProductionEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ProductionEquipmentMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Production Equipment [Member]", "documentation": "Represents production equipment." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6TradeAndOtherPayablesTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee salaries and benefits payable", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r32" ] }, "acst_BrokerWarrantsIssuedMay2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "BrokerWarrantsIssuedMay2018Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Broker Warrants Issued May 2018 [Member]", "documentation": "Represents broker warrants issued May 2018." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r420" ] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Interest Receivable, Current", "terseLabel": "Interest receivable", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r657" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r742" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r420" ] }, "acst_TaxYear2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2036Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2036 [Member]", "documentation": "Identified as tax year 2036.", "terseLabel": "2036" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of diluted net loss per share attributable to common shareholders", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r669" ] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": [ "r42", "r43", "r44" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized foreign exchange (gain) loss", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r101", "r552", "r638", "r718", "r719", "r741" ] }, "acst_PaymentOfIssuanceCostsCommonWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "PaymentOfIssuanceCostsCommonWarrants", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Pyment Of Issuance Cost Warrants", "label": "Payment Of Issuance Costs Common Warrants", "documentation": "Payment Of Issuance Costs Common Warrants" } } }, "auth_ref": [] }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "label": "Exercisable, weighted average fair value", "documentation": "The weighted-average fair value price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Common shares issued in relation to merger with Grade via share-for-share, (in shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r81", "r82", "r111" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r420" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period Shares Employee Stock Purchase agreement", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r15", "r81", "r82", "r111" ] }, "acst_OverallotmentOptionWarrantsIssuedInMay2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "OverallotmentOptionWarrantsIssuedInMay2018Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option Warrants Issued in May 2018 [Member]", "documentation": "Represents over-allotment option warrants issued in May 2018." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r420" ] }, "acst_IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "IssuanceOfCommonSharesAndPreFundedWarrantsThroughPrivatePlacementNetOfOfferingCostsShares", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs,shares", "documentation": "Issuance of common shares and pre-funded warrants through private placement, net of offering costs,shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon the exercise of stock options, Share", "negatedLabel": "Exercised, number of options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r81", "r82", "r111", "r338" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6TradeAndOtherPayablesTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accrued Liabilities, Current, Total", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities and other payables", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r32" ] }, "us-gaap_DepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Deposits [Member]", "documentation": "Amounts held on account by the entity representing a liability to the depositor. Deposits may take various forms (for example, demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits) and may be categorized in multiple ways (such as, foreign and domestic, interest and noninterest bearing)." } } }, "auth_ref": [ "r122" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote15RestructuringCostScheduleOfRestructuringChargesAndPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r272", "r273", "r274", "r275", "r277", "r278", "r279" ] }, "acst_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Laboratory Equipment [Member]", "documentation": "Represent laboratory equipment." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r724" ] }, "us-gaap_PaymentsOfDebtRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtRestructuringCosts", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote15RestructuringCostScheduleOfRestructuringChargesAndPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Restructuring Costs", "terseLabel": "Payments made", "negatedLabel": "Payments made", "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net proceeds", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r167" ] }, "acst_CanadianDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CanadianDepositsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Canadian Deposits [Member]", "documentation": "information pertaining to Canadian deposits." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails": { "parentTag": "acst_IncreaseDecreaseInNonCashWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r10" ] }, "acst_SharesPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "SharesPrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price", "documentation": "Shares Price.", "label": "Shares Price" } } }, "auth_ref": [] }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageFairValue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, weighted average fair value", "label": "Forfeited, weighted average fair value (in CAD per share)", "documentation": "The weighted average fair value of options forfeited during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [] }, "acst_TaxYearTwoThousandFortyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYearTwoThousandFortyThreeMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax year two thousand forty three [Member]", "label": "Tax Year Two Thousand Forty Three [Member]", "terseLabel": "2043" } } }, "auth_ref": [] }, "acst_AtthemarketSalesAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "AtthemarketSalesAgreementTerm", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "At-the-market Sales Agreement, Term (Year)", "label": "acst_AtthemarketSalesAgreementTerm", "documentation": "The term of the at-the-market sales agreement." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liabilities", "label": "Derivative Liability, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r159" ] }, "us-gaap_ShareBasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r102", "r170" ] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosure1" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow disclosure", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r95" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired, number of options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r340" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited, number of options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r339" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted, Weighted average grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r341" ] }, "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfTaxCreditCarryforwardsTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceTables" ], "lang": { "en-us": { "role": { "label": "Summary of Tax Credit Carryforwards [Table Text Block]", "terseLabel": "Summary of Tax Credit Carryforwards", "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances." } } }, "auth_ref": [ "r60" ] }, "acst_ProceedsFromCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ProceedsFromCommonShares", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Common Shares", "label": "Proceeds from Common Shares", "documentation": "Proceeds from Common Shares" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Lease payments discounted incremental borrowing rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r626" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity of short-term investment", "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r39", "r97" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, number of options (in shares)", "periodEndLabel": "Outstanding, number of options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r334", "r335" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, weighted average exercise price", "periodEndLabel": "Outstanding, weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r334", "r335" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Exercisable, number of options (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r336" ] }, "acst_TaxYear2042Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2042Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax year 2042 member", "label": "Tax Year 2042 [Member]", "terseLabel": "2042" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercisable, weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r336" ] }, "acst_PurchaseOfPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "PurchaseOfPreFundedWarrants", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "label": "Purchase of pre funded warrants", "documentation": "Purchase of pre funded warrants" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11SupplementalCashFlowDisclosureChangesInWorkingCapitalItemsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Write-off of operating lease right of use asset", "negatedLabel": "Write-off of operating lease right of use asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r662" ] }, "acst_September2023UsPrivateOfferingWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "September2023UsPrivateOfferingWarrantMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "September 2023 US private offering warrant Member", "documentation": "September 2023 US private offering warrant Member" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r344" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r343" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r324", "r331", "r343", "r344", "r345", "r437", "r461", "r482", "r519", "r520", "r578", "r580", "r583", "r584", "r592", "r601", "r602", "r609", "r618", "r622", "r629", "r632", "r683", "r687", "r730", "r731", "r732", "r733", "r734" ] }, "acst_DividendYieldWarrantLiability": { "xbrltype": "percentItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "DividendYieldWarrantLiability", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Dividend yield warrant liability", "documentation": "Dividend yield warrant liability" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockbasedCompensationScheduleOfWeightedAverageGrantDateFairValueOfAwardsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r345" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "acst_WeightedAverageFairValueCommonWarrantsParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "WeightedAverageFairValueCommonWarrantsParValue", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Fair Value Common Warrants Par Value", "label": "weighted average fair value Common Warrants par value", "documentation": "weighted average fair value Common Warrants par value" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant other observable inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r296", "r325", "r330", "r386", "r435", "r616", "r617", "r619", "r620", "r621" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted prices in active markets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r296", "r325", "r330", "r386", "r434", "r619", "r620", "r621" ] }, "acst_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "PurchaseAgreementMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Agreement [Member]", "label": "Purchase Agreement [Member]", "documentation": "Purchase Agreement [Member]" } } }, "auth_ref": [] }, "acst_ProceedsFromIssuanceOfCommonStockNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ProceedsFromIssuanceOfCommonStockNet", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Issuance of Common Stock, Net", "label": "acst_ProceedsFromIssuanceOfCommonStockNet", "documentation": "The cash inflow from the issuance of common stock, net of issuance cost." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r331", "r461", "r482", "r519", "r520", "r578", "r580", "r583", "r584", "r592", "r601", "r602", "r609", "r618", "r622", "r629", "r687", "r729", "r730", "r731", "r732", "r733", "r734" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r324", "r331", "r343", "r344", "r345", "r437", "r461", "r482", "r519", "r520", "r578", "r580", "r583", "r584", "r592", "r601", "r602", "r609", "r618", "r622", "r629", "r632", "r683", "r687", "r730", "r731", "r732", "r733", "r734" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6TradeAndOtherPayables" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Trade and Other Payables", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r29" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r404", "r429" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote3FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r296", "r325", "r326", "r327", "r328", "r329", "r330", "r386", "r436", "r616", "r617", "r619", "r620", "r621" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-marketable-securities-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r283", "r284", "r285", "r286", "r331", "r461", "r482", "r519", "r520", "r578", "r580", "r583", "r584", "r592", "r601", "r602", "r609", "r618", "r622", "r629", "r687", "r729", "r730", "r731", "r732", "r733", "r734" ] }, "acst_CommonStockVotesPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "CommonStockVotesPerShare", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Votes Per Share", "label": "acst_CommonStockVotesPerShare", "documentation": "The number of votes per one share of common stock." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share, Basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r166", "r184", "r185", "r186", "r187", "r188", "r195", "r197", "r200", "r201", "r202", "r206", "r380", "r381", "r467", "r480", "r606" ] }, "acst_TaxYear2040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2040Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2040 [Member]", "documentation": "Identified as tax year 2040.", "terseLabel": "2040" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeaseOptionToTerminate": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseOptionToTerminate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Option to Terminate", "terseLabel": "Lease expected to terminate date", "documentation": "Description of terms and conditions of option to terminate lessor's operating lease." } } }, "auth_ref": [ "r421" ] }, "acst_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r404", "r429" ] }, "acst_ContractResearchOrganizationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ContractResearchOrganizationsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "CROs", "label": "Contract Research Organizations [Member]", "documentation": "Contract Research Organizations [Member]" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAbstract", "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r404", "r429" ] }, "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Financial Support to Nonconsolidated Legal Entity [Axis]", "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds." } } }, "auth_ref": [ "r0", "r497", "r498" ] }, "acst_ContractManufacturingOrganizationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ContractManufacturingOrganizationsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "CMOs", "label": "Contract Manufacturing Organizations [Member]", "documentation": "Contract Manufacturing Organizations [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax recovery", "terseLabel": "Loss before income tax recovery", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r89", "r120", "r210", "r213", "r215", "r217", "r468", "r477", "r608" ] }, "acst_December2017PublicOfferingBrokerWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "December2017PublicOfferingBrokerWarrantMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "label": "December 2017 public offering broker warrant Member", "documentation": "December 2017 public offering broker warrant Member" } } }, "auth_ref": [] }, "acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment held-for-sale, cost", "label": "Equipment held-for-sale, cost", "documentation": "Of the amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, this element represents the cost component." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4ReceivablesReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Total receivables", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r218", "r219" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "acst_TaxYear2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2029Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2029 [Member]", "documentation": "Identified as tax year 2029.", "terseLabel": "2029" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r404", "r429" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "totalLabel": "Short-term Investments, Total", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r118", "r119", "r658" ] }, "acst_TaxYear2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "TaxYear2037Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceUnrecognizedCanadianFederalTaxCreditsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Year 2037 [Member]", "documentation": "Identified as tax year 2037.", "terseLabel": "2037" } } }, "auth_ref": [] }, "acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Issued in Connection with Public Offering February 2017 [Member]", "documentation": "Represents warrants issued in connection with the public offering in February 2017." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEventsDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Stock options, exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r8", "r22" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 0.0 }, "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax recovery", "terseLabel": "Income tax recovery", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r128", "r137", "r190", "r191", "r212", "r358", "r364", "r481" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote15RestructuringCostScheduleOfRestructuringChargesAndPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r272", "r273", "r277", "r278" ] }, "acst_RiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "RiskFreeInterestRate", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Risk-free interest rate", "documentation": "Risk-free interest rate" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote15RestructuringCostScheduleOfRestructuringChargesAndPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r272", "r273", "r274", "r275", "r277", "r278", "r279" ] }, "acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Equipment held-for-sale, accumulated depreciation", "label": "acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation", "documentation": "Of the amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, this element represents the accumulated depreciation component." } } }, "auth_ref": [] }, "acst_AtthemarketSalesAgreementCommonStockMaximumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "AtthemarketSalesAgreementCommonStockMaximumAmount", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "At-the-market Sales Agreement, Common Stock, Maximum Amount", "label": "acst_AtthemarketSalesAgreementCommonStockMaximumAmount", "documentation": "The maximum amount of common stock that can be sold under the at-the-market sales agreement." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistanceDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r147", "r158", "r172", "r252", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r365", "r367", "r393", "r628", "r685", "r686", "r727" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r351", "r352", "r353", "r499", "r665", "r666", "r667", "r715", "r742" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r56" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance", "periodStartLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17" ] }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14RestructuringAdditionalInformationDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote15RestructuringCostScheduleOfRestructuringChargesAndPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Cost Incurred to Date", "periodStartLabel": "Expenses incurred", "periodEndLabel": "Balance at June 30, 2023", "terseLabel": "Severance costs incurred", "documentation": "Amount of costs incurred to date for the specified restructuring cost." } } }, "auth_ref": [ "r272", "r275", "r277", "r279" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote11LossPerShareScheduleOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Options outstanding", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r313" ] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-5-shortterm-investments-" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r114", "r123", "r124", "r142", "r220", "r221", "r390", "r391" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMachineryAndEquipment", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of equipment", "label": "Payments to Acquire Machinery and Equipment", "documentation": "The cash outflow for acquisition of machinery and equipment." } } }, "auth_ref": [ "r98" ] }, "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfMachineryAndEquipment", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of equipment", "label": "Proceeds from Sale of Machinery and Equipment", "documentation": "The cash inflow from sale of machinery and equipment." } } }, "auth_ref": [ "r96" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r145" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote7Leases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r412" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-1-nature-of-operation-details-textual" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r25" ] }, "acst_ClassDCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.acastipharma.com/20230930", "localname": "ClassDCommonMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnaudited", "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Class D Common [Member]", "documentation": "Class D Common" } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GovernmentAssistanceTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6GovernmentAssistance" ], "lang": { "en-us": { "role": { "terseLabel": "Government assistance", "label": "Government Assistance [Text Block]", "documentation": "The entire disclosure for government assistance." } } }, "auth_ref": [ "r405", "r406", "r407", "r408", "r409" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, weighted average exercise price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r337" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on sale of equipment", "terseLabel": "Gain on sale of equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r11" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote6AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Production equipment (b)", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r70", "r76", "r105", "r107" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, weighted average exercise price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r338" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expired, weighted average exercise price (in CAD per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r340" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-note-3-recent-accounting-pronouncements" ], "lang": { "en-us": { "role": { "terseLabel": "Recent accounting pronouncements", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r135", "r136", "r138", "r144", "r178", "r179", "r182", "r183", "r192", "r193", "r254", "r255", "r361", "r362", "r363", "r374", "r378", "r382", "r383", "r384", "r394", "r395", "r396", "r410", "r411", "r423", "r463", "r464", "r465", "r486", "r487", "r488", "r489", "r490" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r35", "r143", "r163", "r164", "r165", "r175", "r176", "r177", "r181", "r189", "r191", "r207", "r253", "r256", "r314", "r351", "r352", "r353", "r359", "r360", "r369", "r370", "r371", "r372", "r373", "r375", "r379", "r398", "r399", "r400", "r401", "r402", "r403", "r422", "r483", "r484", "r485", "r499", "r572" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationActivitiesWithinTheStockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, weighted average exercise price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r339" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r143", "r175", "r176", "r177", "r181", "r189", "r191", "r253", "r256", "r351", "r352", "r353", "r359", "r360", "r369", "r371", "r372", "r375", "r379", "r483", "r485", "r499", "r742" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule Of Stockholders derivatives Warrants Liability TextBlock", "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityDetailsTextual", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityFairValueMeasurementInputsAndValuationTechniquesDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote9CapitalAndOtherComponentsOfEquityScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote4ReceivablesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r36" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote16SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r428", "r430" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r143", "r163", "r164", "r165", "r175", "r176", "r177", "r181", "r189", "r191", "r207", "r253", "r256", "r314", "r351", "r352", "r353", "r359", "r360", "r369", "r370", "r371", "r372", "r373", "r375", "r379", "r398", "r399", "r400", "r401", "r402", "r403", "r422", "r483", "r484", "r485", "r499", "r572" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/statement-condensed-consolidated-interim-statements-of-changes-in-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r14", "r38", "r370", "r373", "r422", "r483", "r484", "r659", "r660", "r661", "r665", "r666", "r667" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationCompensationExpenseDetails", "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r346", "r354" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": [ "r80", "r116" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote14CommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r80", "r116" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/StatementCondensedConsolidatedInterimStatementsOfLossAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "terseLabel": "Foreign exchange gain (loss)", "totalLabel": "Total other income (loss), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r94" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.acastipharma.com/20230930/taxonomy/role/DisclosureNote10StockBasedCompensationDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r624" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "12", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481410/810-10-15-12" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "35", "Paragraph": "44", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-44" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-7" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-50" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-51" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-52" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-15" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-16" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r647": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-10/tableOfContent" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } }